Topics

Novartis' ofatumumab cut MS relapse rates by more than half versus Sanofi's Aubagio: studies https://www.firstwordpharma.com/node/1666124?tsid=28®ion_id=6 …

11:33 EDT 13 Sep 2019 | FirstWord Pharma

Novartis' ofatumumab cut MS relapse rates by more than half versus Sanofi's Aubagio: studies https://www.firstwordpharma.com/node/1666124?tsid=28&region_id=6 …

Original Article: Novartis' ofatumumab cut MS relapse rates by more than half versus Sanofi's Aubagio: studies https://www.firstwordpharma.com/node/1666124?tsid=28®ion_id=6 …

NEXT ARTICLE

More From BioPortfolio on "Novartis' ofatumumab cut MS relapse rates by more than half versus Sanofi's Aubagio: studies https://www.firstwordpharma.com/node/1666124?tsid=28®ion_id=6 …"

Quick Search

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...